|
FOXJ3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62481139653892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.66133814775094E-16 |
| Normal-vs-Stage2 |
1.66730000028537E-07 |
| Normal-vs-Stage3 |
9.99200722162641E-16 |
| Normal-vs-Stage4 |
1.62847513252018E-12 |
| Stage1-vs-Stage2 |
3.492800E-01 |
| Stage1-vs-Stage3 |
9.841900E-02 |
| Stage1-vs-Stage4 |
1.122450E-02 |
| Stage2-vs-Stage3 |
5.042400E-02 |
| Stage2-vs-Stage4 |
1.369850E-02 |
| Stage3-vs-Stage4 |
4.166800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.69089999996408E-06 |
| Normal-vs-Asian |
1.0749956480538E-11 |
| Caucasian-vs-AfricanAmerican |
3.922200E-01 |
| Caucasian-vs-Asian |
8.990800E-01 |
| AfricanAmerican-vs-Asian |
3.516600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.55351295663786E-15 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.989400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(41-60Yrs) |
1.08357767203415E-13 |
| Normal-vs-Age(61-80Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(81-100Yrs) |
1.785690E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.266800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.666400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.653600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.189400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.846400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.595600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.201600E-04 |
| Classical-VS-Follicular |
8.147000E-01 |
| Classical-VS-Other |
3.115400E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
4.803000E-03 |
| Tall-VS-Other |
5.454200E-01 |
| Tall-VS-Normal |
1.32116539930394E-14 |
| Follicular-VS-Other |
4.651400E-01 |
| Follicular-VS-Normal |
9.12339981340438E-10 |
| Other-VS-Normal |
3.436900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.6621374255883E-15 |
| Normal-vs-N1 |
1.55431223447522E-14 |
| N0-vs-N1 |
2.855600E-02 |
|
|
